Results 131 to 140 of about 908,554 (203)

An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments [PDF]

, 2019
Targeted therapies are playing an increasing role in oncology. Among them, particular attention is nowadays reserved to histology-agnostic treatments.
Alessia Di Lorito, Antonio Marchetti, Fiamma Buttitta, Lara Felicioni   +3 more
core   +1 more source

The value of personalised medicine from a health economics perspective [PDF]

Personalised medicine (PM) aims to use genetic information to better target healthcare to each individual. PM has been met with excitement and anticipation.
Vellekoop, Heleen
core   +5 more sources

Real-World Experience ofNTRKFusion–Positive Thyroid Cancer [PDF]

JCO Precision Oncology, 2022
Jong Chul Park, Arya Ashok, Chienying Liu, Hyunseok Kang   +3 more
openaire   +2 more sources

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Frontiers in Pharmacology
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment ...
Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang   +12 more
doaj   +1 more source

Neurological update: gliomas and other primary brain tumours in adults. [PDF]

, 2017
The emerging understanding of molecular changes in a wide range of brain tumours has led to a significant shift in how these tumours are diagnosed, managed and treated.
Brandner, S, Jaunmuktane, Z
core   +1 more source

Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Laura V. M. Baum, Kimberly L. Johung, Joanna Gibson, Gabriel Cartagena, Daniel J. Boffa, Jill Lacy   +5 more
wiley   +1 more source

NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy

JCO Precision Oncology
PURPOSE Neurotrophic tropomyosin receptor kinase ( NTRK ) fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their responses to targeted therapies are limited.
Vicente R. Marczyk, Sasan Fazeli, Ramona Dadu, Naifa L. Busaidy, Priyanka Iyer, Mimi I. Hu, Steven I. Sherman, Sarah Hamidi, Sayed Mohsen Hosseini, Michelle D. Williams, Salmaan Ahmed, Shaimaa Elzamly, Mark J. Routbort, Raja Luthra, Sinchita Roy-Chowdhuri, Francis Anthony San Lucas, Keyur P. Patel, David S. Hong, Mark Zafereo, Jennifer R. Wang, Anastasios Maniakas, Steven G. Waguespack, Maria E. Cabanillas   +22 more
openaire   +2 more sources

NTRK fusions in solid tumours: what every pathologist needs to know.

Pathology (Sydney), 2023
Minh Anh Nguyen, A. Colebatch, D. Van Beek, G. Tierney, Ruta Gupta, W. Cooper   +5 more
semanticscholar   +1 more source

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors

Acta Neuropathologica Communications
Background Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are found in 1% of gliomas across children and adults. TRK inhibitors are promising therapeutic agents for NTRK-fused gliomas because they are tissue agnostic and cross the blood ...
Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park   +10 more
doaj   +1 more source

Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation

Diagnostic Pathology
Objectives Actionable, solid tumor activating neurotrophic receptor tyrosine kinase (NTRK) fusions are best detected via nucleic acid-based assays, while Pan-TRK immunohistochemistry (IHC) serves as a reasonable screening modality.
Cansu Karakas, Ellen J. Giampoli, Tanzy Love, David G. Hicks, Moises J. Velez   +4 more
doaj   +1 more source